These include baseline cytopenia, extensive bone marrow involvement by metastases, high total tumor volume on PSMA PET/CT, prior exposure to myelosuppressive therapies (such as taxanes), and impaired bone marrow reserve due to cumulative treatment burden [43–46]. Here, FOLH1 is linked to neoplasm.